Abstracts tagged "Sjogren’s syndrome and belimumab"

Abstract Number: 1500 • 2013 ACR/ARHP Annual Meeting
Use Of B Lymphocyte Stimulator Inhibitor Belimumab May Be Associated With a Decrease In the Serum Concentration Of Endothelial Growth Factor In Patients With Primary Sjögren’s Syndrome
Slavica Bobic¹, Sabeeda Kadavath², Linda Gerber³, Ekaterini Zapantis⁴ and Petros V. Efthimiou⁵, ¹Medicine, Lincoln Medical and Mental Health Center, New York, NY, ²Rheumatology, Lincoln Medical and Mental Health Center, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴Lincoln Medical and Mental Health Center, New York, NY, ⁵Medicine/Rheumatology, LM&MHC/Weill Cornell MC, New York, NY
Background/Purpose: , Primary Sjögren's Syndrome (pSjS) is a systemic autoimmune inflammatory disease that primarily affects the lacrimal and salivary glands and is associated with B…
Abstract Number: 2555 • 2012 ACR/ARHP Annual Meeting
Results of the Beliss Study, the First Open Phase 2 Study of Belimumab in Primary Sjogren’s Syndrome
Xavier Mariette¹, Luca Quartuccio², Raphaèle Seror³, Sara Salvin⁴, Frederic Desmoulins¹, Martina Fabris⁵, Sara Villeneuve⁶, Philippe Ravaud⁷ and Salvatore De Vita², ¹Rheumatology, Université Paris-Sud, Le Kremlin Bicetre, France, ²Rheumatology, DSMB, University Hospital Santa Maria della Misericordia, Udine, Italy, ³Rheumatology, Bicetre university hospital, LE Kremlin-Bicetre, France, ⁴Rheumatology Clinic, DSMB, University of Udine, Italy, Udine, Italy, ⁵Institute of Clinical Pathology, Udine, Italy, ⁶Epidemiology departement, Hospital Hotel dieu, Paris, France, ⁷Epidemiology, Hopital Hotel Dieu, Paris Descartes University, Paris, France
Background/Purpose: The BAFF (or BLyS) cytokine plays a key role in pathogenesis of primary Sjogren’s syndrome (pSS). Belimumab, the first biological treatment inhibiting soluble BAFF,…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].